Severity of Sarcopenia in Parkinson's Disease

NCT07014514 | Completed

• 1 other identifier: E-59394181-604.01-112205
• Study Type: observational
• Target: 65
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to determine the prevalence of sarcopenia and dynapenia in Parkinson's disease patients, classified into early-stage (\<2.5) and moderate-stage (≥2.5) according to the Modified Hoehn and Yahr scale, and healthy controls using the ICF-based ISarcoPRM algorithm, and to examine the differences in regional muscle morphology, muscle strength, and physical performance between groups.This study was conducted as a cross-sectional research. The study included 43 Parkinson's disease patients aged 50-75 years, classified as stages 1-3 according to the Modified Hoehn-Yahr Scale, and 22 healthy individuals with similar demographic characteristics. Parkinson's disease patients were divided into two subgroups according to the Modified Hoehn-Yahr Scale: early stage (\<2.5) and intermediate stage (≥2.5). Demographic information of all participants was recorded, and clinical evaluations were performed. Parkinson's disease staging was assessed using the Modified Hoehn-Yahr Scale. Muscle mass was assessed using ultrasonography to measure anterior femoral muscle thickness. Muscle strength was measured by handgrip strength, and physical performance was assessed using a five-count sit-up test.

Conditions

Parkinson Disease

Keywords

sarcopenia; ultrasonography

Outcome Measures

Primary Outcomes (3)

• Ultrasonographic Measurement

  For sarcopenia evaluation, anterior thigh muscle thickness will be measured by ultrasonography.

  Baseline

• Five Times Sit to Stand Test

  This test measures the time it takes for an individual to stand up and sit down 5 times as quickly as possible, starting from a sitting position without using their arms.

  Baseline

• Hand Grip Strength

  In this test, the individual will sit on a chair with their feet flat on the floor. The Jamar Hand Dynamometer will be used for measurement. They will be asked to squeeze the dynamometer firmly with their shoulders adducted and in neutral rotation, their elbows in 90-degree flexion, their forearms neutral and supported, and their wrists neutral. 3 repetitions will be done and the average will be taken.

  Baseline

Study Arms (3)

Early Stage

Patients with Early Stage Parkinson's Disease

Control Group

Healthy individuals with similar demographic characteristics

Moderate Stage

Patients with Moderate Stage Parkinson's Disease

Eligibility Criteria

• Age: 40 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Among the patients diagnosed with Parkinson's Disease who come to the neurology clinic for routine examination, patients who meet the appropriate inclusion criteria will be evaluated by the Neurology Specialist and included in the study.

You may qualify if:

• Score between 24 and 30 on the Mini Mental State Examination
• Be diagnosed with Parkinson's Disease by a neurologist
• Stage 1-3 on the Modified Hoehn and Yahr Scale

You may not qualify if:

• Inability to communicate verbally
• Elderly people with severe visual impairment, neurological disorders in addition to Parkinson's and/or congestive heart failure
• Older adults in whom exercise is not recommended

Sponsors & Collaborators

• Ankara University: lead

Study Sites (1)

Atılım University

Ankara, Turkey (Türkiye)

Location

Related Publications (2)

• Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Fragala MS, Kenny AM, Kiel DP, Kritchevsky SB, Shardell MD, Dam TT, Vassileva MT. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547-58. doi: 10.1093/gerona/glu010.

  PMID: 24737557 RESULT

• Kara M, Kaymak B, Frontera W, Ata AM, Ricci V, Ekiz T, Chang KV, Han DS, Michail X, Quittan M, Lim JY, Bean JF, Franchignoni F, Ozcakar L. Diagnosing sarcopenia: Functional perspectives and a new algorithm from the ISarcoPRM. J Rehabil Med. 2021 Jun 21;53(6):jrm00209. doi: 10.2340/16501977-2851.

  PMID: 34121127 RESULT

MeSH Terms

Conditions

Parkinson Disease; Sarcopenia

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Officials

• Süleyman Korkusuz, PhD

  Atılım University

  STUDY CHAIR

• Ayla Fil Balkan, Assoc Prof

  Hacettepe University

  STUDY CHAIR

• Gül Yalçın Çakmaklı, Assoc Prof

  Hacettepe University

  STUDY CHAIR

• Büşra Seçkinoğulları Korkusuz, PhD

  Ankara University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: May 30, 2025
• First Posted: June 11, 2025
• Study Start: June 20, 2025
• Primary Completion: September 20, 2025
• Study Completion: October 25, 2025
• Last Updated: March 25, 2026

Record last verified: 2025-07

Locations

TU (1)